BCLI

Brainstorm Cell Therapeutics (BCLI)

About Brainstorm Cell Therapeutics (BCLI)

Brainstorm Cell Therapeutics, Inc. is a biotechnology company, which develops and commercializes autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis, Progressive Multiple Sclerosis, Alzheimer's disease, and other neurodegenerative diseases. Its pipeline, NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and improve neurological function. The company was founded by Irit Arbel on September 22, 2000 and is headquartered in New York, NY.

Details

Daily high
$2.54
Daily low
$2.30
Price at open
$2.37
52 Week High
$11.89
52 Week Low
$2.01
Market cap
12.6M
Dividend yield
0.00%
Volume
45,003
Avg. volume
33,272
P/E ratio
-.70

Brainstorm Cell Therapeutics News

Details

Daily high
$2.54
Daily low
$2.30
Price at open
$2.37
52 Week High
$11.89
52 Week Low
$2.01
Market cap
12.6M
Dividend yield
0.00%
Volume
45,003
Avg. volume
33,272
P/E ratio
-.70